Entries by Infixion Bioscience

With promising in vitro data utilizing ASOs to boost NF1 expression, iNFixon launches seed financing round to fund in vivo animal studies

iNFixion Bioscience is developing an antisense oligonucleotide (ASO) therapy designed to boost NF1 protein expression, aiming to address the underlying root cause driver of neurofibromatosis type 1 (NF1) symptoms, namely NF1 protein haploinsufficiency. Following promising in vitro data, demonstrating the potential for this approach across multiple human cell types, the company has launched a seed […]

iNFixion CEO and investors attend NF advocacy event in DC with NF Network

Herb Sarnoff, CEO of iNFixion, along with several company investors joined forces in support of the Neurofibromatosis Network’s annual three-day advocacy trip to Washington, DC. Alongside over 100 NF advocates from across the country, Herb and his team met with Congressional leaders to push for continued federal funding of NF scientific research through both the […]

iNFixion team attends Children’s Tumor Foundation Global NF Conference in Brussels

Members of iNFixion’s executive team headed to Brussels for the 2024 Global NF Conference, the leading international meeting shaping the future of neurofibromatosis and schwannomatosis research and clinical care. Organized by the Children’s Tumor Foundation and the European NF Group, this event brought together over 1,000 experts, clinicians, researchers, and advocates. The team was honored […]

iNFixion is awarded Gilbert Family Foundation grant to generate new NF1 preclinical models focused on neurocognition

The Gilbert Family Foundation has awarded a three-year grant to iNFixion Bioscience as part of its Next Generation Neurofibromatosis Models Initiative to develop a more human-translatable rodent model for the cognitive and learning deficits experienced by individuals with NF1.  This project builds on research from Dr. Jared Young’s lab at UCSD, which will conduct all […]

iNFixion Bioscience published peer-reviewed paper on haploinsufficiency correction therapy for NF1

iNFixion published a peer-reviewed paper in the Journal of Translational Genetics and Genomics highlighting the rationale for haploinsufficiency correction therapy (HCT) as a potential treatment for neurofibromatosis type 1 (NF1). Evidence supports that a reduced level of functional neurofibromin (NF1 protein) in cells harboring an NF1 mutation plays a direct role in driving NF1 manifestations. […]

The DOD Neurofibromatosis Research Program awards grant to collaborative project between James Walker’s Lab at MGH and iNFixion Bioscience

A three-year grant through the DOD Neurofibromatosis Research Program (NFRP) has been awarded to Dr. James Walker’s lab at Massachusetts General Hospital (MGH), with iNFixion Bioscience as a sub-awardee, to develop and validate a lentiviral CRISPRa/Cas9 tool designed to enhance NF1 protein expression. The Walker Lab will design the CRISPRa/Cas9 compounds for testing, while iNFixion […]

Ⓒ iNFixion Bioscience (2017-2025). All rights reserved.